Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... software invited to engage around the theme, ,Commercial Opportunities ...   Elsevier , a ... and services, will host a gathering of some of ... and trends impacting healthcare today and in the future. ...
(Date:9/30/2014)... Applying a well-known optical phenomenon called thin-film interference, ... demonstrated the ability to "paint" ultra-thin coatings onto ... for making future, flexible electronic devices, creating advanced ... rocket ships and spacecraft with extremely lightweight decorative ... water, it becomes iridescent, revealing a myriad of ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... Report Details Biosimilar drugs – ... Do you want to find sales potentials of ... for those biological drugs from 2014, helping you ... data, R&D trends, opportunities and selling prospects. In ... 2024 at overall world market, therapeutic class, molecule ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Taking thin films to the extreme 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... scientists observe a reaction moving at greater than 10 meters ... feat some would say is nearly impossible. But ... dynamic transmission electron microscope (DTEM). DTEM,s ability to ... it,s happening has earned it one of the 10 winning ...
... , Aug. 2 Octapharma USA today ... is the Rush Hemophilia & Thrombophilia Center at Rush ... focused on human protein therapies in hematology, immune therapy, intensive care and emergency ... Leonard A. ...
... Aug. 2 Tengion Inc. (Nasdaq: TNGN ... to the position of Chief Financial Officer.  Mr. Davis comes to Tengion ... technologies to develop improved protein therapeutics. At its peak, Neose employed 200 ... , , ...
Cached Biology Technology:Livermore's DTEM earns innovation award from Microscopy Today 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2
(Date:9/30/2014)... of Medicine reports positive results of a phase ... subset of lung cancer marked by rearrangement of the ... with advanced non-small cell lung cancer testing positive for ... with 3 complete responses and 33 partial responses. Median ... disease to resume its growth after being slowed by ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... of perilous threats in today,s ocean. From overfishing ... fragile coral ecosystems are disappearing at unprecedented rates ... of corals surrounding the island of Moorea in ... tropical environment: coral guard-crabs. New research from the ... scientist Seabird McKeon and the museum,s predoctoral fellow ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... Smart Search & Match,the leading provider of high-performance ... has joined the company as Product Marketing Manager. ... 15 years of product and marketing management,experience to ... many high-tech products and solutions worldwide. He has ...
... the human body in ways never imagined only a ... population of patients who are newly susceptible to opportunistic ... formidable clinical opponent, and foremost among them is ... from ASM Press. "This volume has been ...
... of the global population living in cities reached 50 ... exciting new book series which brings together leading experts ... all over the world. The aim of the ... facing the architects, planners, developers and inhabitants of the ...
Cached Biology News:New text focuses on formidable opportunistic fungus 2Springer looks ahead to the Future City 2
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
Biology Products: